POC(Point-of-Care) 혈당 검사 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Point-of-Care Glucose Testing Market was valued at USD 3.4 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to 2032. Recent advancements in point-of-care (POC) glucose testing have significantly improved the accuracy, convenience, and management of diabetes. Innovations such as integration with continuous glucose monitoring systems and advanced sensor technologies are transforming glucose level monitoring and management. In February 2023, Dexcom launched its next-generation Dexcom G7 CGM System, featuring a sensor 60% smaller than its predecessor, the G6. The G7 provides real-time glucose data directly to smartphones or smartwatches, eliminating the need for fingerstick tests. It is designed for individuals with type 1, type 2, or gestational diabetes.

Many point-of-care glucose meters now include Bluetooth or Wi-Fi capabilities for seamless data transfer to smartphones, tablets, or cloud platforms. This enhances data management and enables remote monitoring by healthcare professionals. Abbott's FreeStyle Libre 3 offers real-time glucose readings through a compact sensor and integrates with the FreeStyle LibreLink app for continuous tracking and data sharing. The market is segmented by product type into lancing devices, test strips, and blood-glucose meters.

The test strips segment is forecasted to reach USD 2.3 billion by 2032. Test strips offer high accuracy and precision in glucose measurement, which is essential for effective diabetes management. The user-friendly design of test strips requires minimal training, making them accessible for both patients and healthcare providers. The process involves placing a small blood sample on the strip and inserting it into a glucose meter, facilitating ease of use. The market is bifurcated by end-use into hospitals, clinics, diagnostic centers, home care settings, and other end-users.

The home care settings segment accounted for USD 1.3 billion in 2023. Home care settings offer significant advantages for point-of-care glucose testing. They allow individuals with diabetes to manage their condition conveniently from home, reducing the need for frequent healthcare facility visits. The point-of-care glucose testing market in the UK is expected to experience significant growth from 2024 to 2032. The UK benefits from a well-established and sophisticated healthcare infrastructure. The National Health Service (NHS) provides a comprehensive framework for the integration of new medical technologies, including point-of-care (POC) glucose testing systems.The UK is a hub for medical research and innovation. Numerous universities and research institutions focus on advancing diagnostic technologies, including glucose monitoring. This research contributes to the development of more accurate, efficient, and user-friendly point-of-care glucose testing devices.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of diabetes
    • 3.2.1.2 Technological advancements in glucose monitoring
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Growing adoption of continuous glucose monitors
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of advanced devices
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Lancing devices
• 5.3 Test strips
• 5.4 Blood-glucose meter

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Diagnostic centers
• 6.5 Home care settings
• 6.6 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
  • 7.3.7 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 ARKRAY, Inc.
• 8.3 ACON Laboratories, Inc.
• 8.4 B. Braun Melsungen AG
• 8.5 Dexcom, Inc.
• 8.6 EKF Diagnostics Holdings plc
• 8.7 F. Hoffmann-La Roche Ltd.
• 8.8 Medtronic plc
• 8.9 Nipro Corporation
• 8.10 Nova Biomedical Corporation
• 8.11 PHC Holdings
• 8.12 Prodigy Diabetes Care, LLC.
• 8.13 Platinum Equity Advisors, LLC.
• 8.14 Sanofi
• 8.15 Sinocare